Michael Christian Sulz1, Emanuel Burri2, Pierre Michetti3, Gerhard Rogler4, Laurent Peyrin-Biroulet5, Frank Seibold6. 1. Department of Gastroenterology and Hepatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, michael.sulz@kssg.ch. 2. Gastroenterology and Hepatology, University Medical Clinic, Cantonal Hospital Baselland, Liestal, Switzerland. 3. Centre de Gastroentérologie Beaulieu SA and Division of Gastroenterology, Lausanne University Medical Center, Lausanne, Switzerland. 4. Department of Gastroenterology and Hepatology, University Hospital Zurich and Zurich University, Zürich, Switzerland. 5. Department of Gastroenterology and Inserm U954, Nancy University Hospital, Lorraine University, Vandoeuvre-Lès-Nancy, France. 6. Praxis Balsiger Seibold und Partner, Crohn Colitis Zentrum, Bern und Université de Fribourg, Gastroenterologie, Bern, Switzerland.
Abstract
BACKGROUND: Treatment of Crohn's disease (CD) patients is complex as therapy choices depend on a variety of factors, such as location and severity of inflammation, disease behavior (inflammatory, stricturing or penetrating) but also comorbidities, extra-intestinal manifestations, the patient's age, and previous therapies. Subsequently, the choice of treatment should be tailored to the individual patient. SUMMARY: This article gives the reader therapy algorithms as a guide through different CD scenarios to support the physician's decision making. New compounds introduced in CD therapy in recent years justify such an update on standard approaches. Ustekinumab and vedolizumab and their positions within the treatment options are discussed. Fistulizing perianal disease and postoperative medical prophylaxis are depicted in separate chapters with own algorithms. Key Messages: In recent years, a variety of new drugs became available to treat patients with CD - especially those who are antitumor necrosis factor (TNF) experienced with ongoing inflammation. The definitive role of vedolizumab and ustekinumab is not yet fully clarified. However, with the advantage of good safety profiles over TNF-inhibitors, these drugs will be more frequently used in the near future, also as first-line biologicals, compared to TNF-inhibitors. Concerning treatment of fistulizing disease, the knowledge of the exact anatomy of the fistula is of major importance. An interdisciplinary discussion involving gastroenterologists, surgeons, and in some cases gynecologists may help to optimize the treatment plan. Regarding the postsurgical setting in CD patients, according to the very recent Cochrane Network meta-analysis, mesalazine should be at least positioned equivalent to thiopurines and TNF-inhibitors, as shown in our algorithm.
BACKGROUND: Treatment of Crohn's disease (CD) patients is complex as therapy choices depend on a variety of factors, such as location and severity of inflammation, disease behavior (inflammatory, stricturing or penetrating) but also comorbidities, extra-intestinal manifestations, the patient's age, and previous therapies. Subsequently, the choice of treatment should be tailored to the individual patient. SUMMARY: This article gives the reader therapy algorithms as a guide through different CD scenarios to support the physician's decision making. New compounds introduced in CD therapy in recent years justify such an update on standard approaches. Ustekinumab and vedolizumab and their positions within the treatment options are discussed. Fistulizing perianal disease and postoperative medical prophylaxis are depicted in separate chapters with own algorithms. Key Messages: In recent years, a variety of new drugs became available to treat patients with CD - especially those who are antitumor necrosis factor (TNF) experienced with ongoing inflammation. The definitive role of vedolizumab and ustekinumab is not yet fully clarified. However, with the advantage of good safety profiles over TNF-inhibitors, these drugs will be more frequently used in the near future, also as first-line biologicals, compared to TNF-inhibitors. Concerning treatment of fistulizing disease, the knowledge of the exact anatomy of the fistula is of major importance. An interdisciplinary discussion involving gastroenterologists, surgeons, and in some cases gynecologists may help to optimize the treatment plan. Regarding the postsurgical setting in CDpatients, according to the very recent Cochrane Network meta-analysis, mesalazine should be at least positioned equivalent to thiopurines and TNF-inhibitors, as shown in our algorithm.
Authors: Fotios S Fousekis; Ioannis V Mitselos; Kostas Tepelenis; George Pappas-Gogos; Konstantinos H Katsanos; Georgios D Lianos; Francesco Frattini; Konstantinos Vlachos; Dimitrios K Christodoulou Journal: J Clin Med Date: 2022-04-23 Impact factor: 4.964
Authors: Charlotte M Verburgt; Mohammed Ghiboub; Marc A Benninga; Wouter J de Jonge; Johan E Van Limbergen Journal: Nutrients Date: 2021-01-13 Impact factor: 5.717
Authors: David Schöler; Karel Kostev; Maximilian Peters; Cosmin Zamfir; Agnieszka Wolk; Christoph Roderburg; Sven H Loosen Journal: J Clin Med Date: 2022-08-05 Impact factor: 4.964
Authors: Karam Elsolh; Daniel Tham; Michael A Scaffidi; Nikko Gimpaya; Rishi Bansal; Nazi Torabi; Juana Li; Yash Verma; Rishad Khan; Samir C Grover Journal: J Can Assoc Gastroenterol Date: 2022-06-01